Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEACOAST: Niacin ER/Simvastatin in Dyslipidemia
NCT00082251Phase 3Completed
- Sponsor
- Kos Pharmaceuticals, Inc.
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of niacin and simvastatin in hyperlipidemia and dyslipidemia (6 arms), sponsored by Kos Pharmaceuticals, Inc. Primary endpoint: Non-High-Density Lipoprotein Cholesterol at 24 weeks. Status: completed.
02
Drugs
niacinsimvastatin
03
Conditions
hyperlipidemiadyslipidemia
Beyond the preview
Go deeper on NCT00082251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082251.